이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hansoh Pharmaceutical Group 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Huijuan Zhong

최고 경영자

CN¥14.8m

총 보상

CEO 급여 비율	49.6%
CEO 임기	8.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	8.6yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Huijuan Zhong 의 보수는 Hansoh Pharmaceutical Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥5b
Mar 31 2024	n/a	n/a	CN¥4b
Dec 31 2023	CN¥15m	CN¥7m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥11m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥16m	CN¥8m	CN¥3b

보상 대 시장: Huijuan 의 총 보상 ($USD 2.08M )은 Hong Kong 시장( $USD 789.58K ).

보상과 수익: Huijuan 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Huijuan Zhong (63 yo)

8.8yrs

테뉴어

CN¥14,807,000

보상

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...

리더십 팀

이름	위치	테뉴어	보상	소유권
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	데이터 없음
Aifeng Lyu	Executive Director	8.6yrs	CN¥9.39m	0.023% HK$ 30.6m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% HK$ 27.5m
Min Hu	VP & CFO	no data	데이터 없음	데이터 없음
Chih-Hung Lee	Chief of Science Officer	2.5yrs	데이터 없음	데이터 없음
Chuanhe Xu	Senior Vice President	15.6yrs	데이터 없음	데이터 없음
Weiyong Sun	Chief Commercial Officer	no data	데이터 없음	데이터 없음
Shengli Zhong	Joint Company Secretary & Senior VP	6.2yrs	데이터 없음	데이터 없음
Sze Wai Tam	Joint Company Secretary	less than a year	데이터 없음	데이터 없음

8.6yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 3692 의 관리팀은 노련하고 경험 (평균 재직 기간 8.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	데이터 없음
Aifeng Lyu	Executive Director	8.6yrs	CN¥9.39m	0.023% HK$ 30.6m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% HK$ 27.5m
Guoqiang Lin	Independent Non-Executive Director	5.4yrs	CN¥360.00k	데이터 없음
Sheung Wai Chan	Independent Non-Executive Director	5.4yrs	CN¥360.00k	데이터 없음
Dongtao Yang	Independent Non-Executive Director	5.4yrs	CN¥360.00k	데이터 없음

7.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 3692 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Hansoh Pharmaceutical Group 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Insufficient new directors

Insufficient new directors

Recent updates

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets"

Hansoh Pharmaceutical Group Company Limited Announces That "Ibrexafungerp Tablets" Has Been Granted A Clinical Trial

Non-Executive Director Cuifang Ma has left the company

First half 2021 earnings released: EPS CN¥0.22 (vs CN¥0.21 in 1H 2020)

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Receives Approval by the National Medical Products Administration of the People ' S Republic of China for Class 1 Innovative Drug Tenofovir Amibufenamide Tablets

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ameile for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval of "Bortezomib for Injection"

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited Recommends a Final Dividend for the Year Ended December 31, 2020, Payable on July 5, 2021

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021